Dexterra Announces Date of Q2 2025 Results and Conference Call
The conference call dial in number is 1-844-763-8274
A live webcast of the conference call will be accessible on Dexterra's website at https://ir.dexterra.com/events-presentations by selecting the Q2 2025 Results webcast link.
An archived recording of the conference call will be available approximately one hour after the completion of the call until September 6, 2025 by dialing 1-855-669-9658, passcode 3972185.
About Dexterra
Dexterra employs over 9,000 people, delivering a range of support services for the creation, management, and operation of infrastructure across Canada and the U.S.
Powered by people, Dexterra brings best-in-class regional expertise to every challenge and delivers innovative solutions, giving clients confidence in their day-to-day operations. Activities include a comprehensive range of integrated facilities management services, industry-leading workforce accommodation solutions, and other support services for diverse clients in the public and private sectors.
You can also visit our website at dexterra.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
22 minutes ago
- Cision Canada
CHAMPION IRON TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON AUGUST 27, 2025 (MONTRÉAL) / AUGUST 28, 2025 (SYDNEY)
MONTRÉAL, Aug. 13, 2025 /CNW/ - SYDNEY, August 14, 2025 - Champion Iron Limited (TSX: CIA) (ASX: CIA) (OTCQX: CIAFF) ("Champion" or the "Company") announces that, further to the various filings previously made in this regard, its Annual General Meeting of Shareholders (the "Meeting") will be held on Wednesday, August 27, 2025, at 5:00 PM (Montréal time) / Thursday, August 28, 2025, at 7:00 AM (Sydney time). Information relating to the Meeting can be found under the Company's filings on SEDAR+ ( the ASX ( and the Company's website under the Investors section ( The specific details for the Meeting are as follows: A live audio webcast will be available the day of the meeting and the webcast recording will be accessible through Champion's website at Access to the webcast: About Champion Iron Limited Champion, through its wholly-owned subsidiary Quebec Iron Ore Inc., owns and operates the Bloom Lake Mining Complex located on the south end of the Labrador Trough, approximately 13 kilometres north of Fermont, Québec. Bloom Lake is an open-pit operation with two concentration plants that primarily source energy from renewable hydroelectric power, having a combined nameplate capacity of 15M wmt per year that produce lower contaminant high-grade 66.2% Fe iron ore concentrate with a proven ability to produce a 67.5% Fe direct reduction quality iron ore concentrate. Benefiting from one of the highest purity resources globally, Champion is investing to upgrade half of Bloom Lake's mine capacity to a direct reduction quality pellet feed iron ore with up to 69% Fe. Bloom Lake's high-grade and lower contaminant iron ore products have attracted a premium to the Platts IODEX 62% Fe iron ore benchmark. Champion ships iron ore concentrate from Bloom Lake by rail, to a ship loading port in Sept-Îles, Québec, and has delivered its iron ore concentrate globally, including in China, Japan, the Middle East, Europe, South Korea, India and Canada. In addition to Bloom Lake, Champion owns the Kamistiatusset mining properties, a project with an expected annual production of 9M wmt per year of direct reduction quality iron grading above 67.5% Fe, located near available infrastructure and only 21 kilometres southeast of Bloom Lake. On July 21, 2025, Champion entered into a definitive framework agreement with Nippon Steel Corporation and Sojitz Corporation to form a partnership for the shared ownership and potential development of the Kami project. Champion also owns a portfolio of exploration and development projects in the Labrador Trough, including the Cluster II portfolio of properties, located within 60 kilometres south of Bloom Lake. For additional information on Champion Iron Limited, please visit our website at: This press release has been authorized for release to the market by the CEO of Champion Iron Limited, David Cataford. SOURCE Champion Iron Limited
Cision Canada
22 minutes ago
- Cision Canada
DRI Healthcare Reports Second Quarter 2025 Results
Subsequent to the end of the quarter, completed the previously announced transaction to internalize its investment management function Portfolio assets generate Total Income of $44.1 million Reactivated NCIB and repurchased ~958 K units for $9.1 million, while redeeming $10 million of Series C Preferred Securities for $9.5 million TORONTO, Aug. 13, 2025 /CNW/ - DRI Healthcare Trust (TSX: (TSX: DHT.U) ("DRI Healthcare") today announced its financial results for the quarter ended June 30, 2025. DRI Healthcare's second quarter 2025 financial statements and Management's Discussion & Analysis ("MD&A") have been filed on SEDAR+ ( All dollar amounts are expressed in U.S. dollars unless otherwise indicated. "Over the past few months, DRI Healthcare has undergone a truly transformational period. By successfully internalizing our external manager, we now have direct alignment between our management team and our unitholders—every decision is focused squarely on creating long-term value.", said Ali Hedayat, DRI Healthcare's Chief Executive Officer. "We've integrated a deeply committed team, sharpened our operating discipline, and are executing with the benefit of a high-quality portfolio of assets with durable growth potential. I'm especially proud that our first pre-approval investment has now been approved, validating our underwriting approach and accelerating future cash flow visibility. Together, these milestones position DRI Healthcare for stronger, more sustainable returns in the years ahead." Q2 Highlights Total Income of $44.1 million; Total Cash Receipts of $40.2 million 1; Adjusted EBITDA of $30.4 million 2; Comprehensive Loss of $0.7 million; Adjusted Cash Earnings per Unit of $0.51 (basic and diluted) 1,2; Received Toronto Stock Exchange ("TSX") approval for normal course issuer bid to allow DRI Healthcare to acquire up to 3,148,536 units of DRI Healthcare ("Units") between May 20, 2025 and May 19, 2026. Repurchased 958,279 Units under its Normal Course Issuer Bid ("NCIB") at an average price of $9.54, totaling $9.1 million under the Automated Purchase Plan ("AUPP"). Paid a quarterly cash distribution of US$0.10 per Unit on July 18, 2025. Subsequent to Quarter End Completed the previously announced transaction to internalize its investment management function, terminated the management agreement with DRI Capital Inc. ("DRI Capital") for a termination payment of $48 million, and acquired the relevant assets of DRI Capital for a purchase price of $1 million. Completed the funding of the Ekterly (sebetralstat) optional payment of $22 million which increases DRI Healthcare's royalty entitlement on net sales up to and including the first $500 million from 5.0% to 6.0% and the potential one-time sales-based milestones payment to KalVista from $50 million to $57 million. Our total investment in Ekterly is now $127 million. Repurchased 208,580 Units under its NCIB at an average price of US$10.24 totaling $2.1 million under the AUPP. Declared a quarterly cash distribution of US$0.10 per Unit for the third quarter of 2025, payable on October 20, 2025 to unitholders of record on September 30, 2025. _________________________ 1 Total Cash Receipts and Adjusted EBITDA are non-GAAP financial measures. Adjusted Cash Earnings per Unit is a non-GAAP ratio. These measures are not standardized measures under IFRS and might not be comparable to similar financial measures disclosed by other issuers. The reconciliation of these measures can be found later in this press release and in DRI Healthcare's MD&A. 2 The weighted average number of basic and diluted units for the purposes of calculating Earnings per Unit for the three months ended June 30, 2025 were 55,685,363 Units. Financial Highlights Three months ended Six months ended (thousands of US dollars, except per Unit amounts) June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Total income 44,130 41,604 88,158 83,671 Management fees 2,657 2,825 6,733 6,989 Performance fees — — 533 231 Amortization of royalty assets 24,751 25,679 49,496 50,725 Impairment of royalty assets — 820 — 5,200 Other expenses 15,375 15,825 31,801 29,800 Gain (loss) on preferred securities (971) 2,176 (971) 2,176 Other loss — (764) — (1,575) Net earnings (loss) 376 (2,133) (1,376) (8,673) Net unrealized gain (loss) on derivative instruments (1,076) 228 (1,156) 1,425 Comprehensive earnings (loss) (700) (1,905) (2,532) (7,248) Net earnings (loss) per Unit – basic 0.01 (0.04) (0.02) (0.15) Net earnings (loss) per Unit – diluted 0.01 (0.04) (0.02) (0.15) Total Cash Receipts 1 40,152 42,955 102,142 106,472 Adjusted EBITDA 1 30,372 32,903 82,031 88,367 Adjusted EBITDA Margin 1 76 % 77 % 80 % 83 % Adjusted Cash Earnings per Unit – Basic 1 0.51 0.49 0.95 0.97 Adjusted Cash Earnings per Unit – Diluted 1 0.51 0.49 0.95 0.97 Weighted average number of Units – Basic 55,685,363 56,426,259 55,743,876 56,392,250 Weighted average number of Units – Diluted 55,685,363 56,426,259 55,743,876 56,392,250 Asset Performance As at June 30, 2025, DRI Healthcare's portfolio included 28 royalty streams on 21 products that address a variety of therapeutic areas, such as oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders and immunology. On June 30, 2025, the royalty asset portfolio had a book value, net of accumulated amortization, of $774.4 million, which during the three and six months ended June 30, 2025 generated Total Cash Royalty Receipts 1 of $40.2 million and $102.1 million, respectively, and royalty income of $44.8 million and $84.4 million, respectively. On June 30, 2025, the financial royalty asset had a book value of $54.2 million and generated a gain (loss) on the change in its fair value of $(0.9) million and $1.7 million, respectively, during the three and six months ended June 30, 2025. (thousands of US dollars) Cash Receipts Three months ended Six months ended Royalty Asset Therapeutic Area Marketer(s) June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Casgevy Hematology Vertex Pharmaceuticals — — 5,000 — Empaveli/Syfovre Hematology/Ophthalmology Apellis, Sobi 147 2,552 1,272 2,575 Eylea I Ophthalmology Regeneron, Bayer, Santen 1,158 1,321 2,680 2,728 Eylea II Ophthalmology Regeneron, Bayer, Santen 248 285 579 590 Natpara Endocrinology Takeda 222 695 501 1,263 Omidria Ophthalmology Rayner Surgical 8,993 11,261 16,987 19,821 Oracea Dermatology Galderma 1,046 1,886 2,580 4,336 Orserdu I 1 Oncology Menarini 6,410 5,315 14,920 13,335 Orserdu II 1 Oncology Menarini 6,409 3,633 29,329 27,171 Rydapt 2 Oncology Novartis 777 1,953 1,936 4,176 Spinraza Neurology Biogen 3,781 3,272 7,743 7,115 Vonjo I Hematology Sobi 2,553 2,887 5,648 5,789 Vonjo II 1 Hematology Sobi 576 615 1,351 6,220 Xenpozyme Lysosomal Storage Disorder Sanofi 1,913 662 1,913 662 Xolair Immunology Roche, Novartis 2,162 1,666 4,535 4,112 Zejula Oncology GSK 1,103 932 2,052 1,894 Zytiga Oncology Johnson & Johnson 2,230 3,546 2,230 3,546 Other Products 3 Various Various 424 474 886 1,139 Total Cash Royalty Receipts, Cash Receipts and Normalized Cash Receipts 4 40,152 42,955 102,142 106,472 ____________________________ 1 Cash receipts for Orserdu II and Orserdu I for the six months ended June 30, 2025 include $17,593 and $633, respectively, for reclamation of previous royalty deductions. Cash receipts for the six months ended June 30, 2024 include milestone royalty receipts of $2,104 from Orserdu I, $18,939 from Orserdu II and $5,000 from Vonjo II received in Q1 2024. 2 Cash receipts for the six months ended June 30, 2024 includes $1,000 in additional cash receipts related to a one-time payment received in Q1 2024. 3 Other Products includes royalty income from certain other royalty assets as well as royalty assets which are fully amortized and, where applicable, the entitlements to which have generally expired. Comparative figures for royalty assets Simponi, Stelara and Ilaris are included in Other products. 4 Total Cash Receipts, Total Cash Royalty Receipts and Normalized Total Cash Receipts are non-GAAP financial measures. These measures are not standardized measures under IFRS and might not be comparable to similar financial measures disclosed by other issuers. The reconciliation of these measures can be found later in this press release and in the DRI Healthcare's MD&A. Liquidity and Capital On June 30, 2025, DRI Healthcare had cash and cash equivalents of $82.5 million. DRI Healthcare's credit facility had an outstanding principal balance of $344.7 million on June 30, 2025. DRI Healthcare had 55,500,947 Units issued and outstanding on June 30, 2025. Distributions On May 12, 2025, the board of trustees approved a quarterly cash distribution of $0.10 per Unit to unitholders of record as of June 30, 2025, which was paid on July 18, 2025. DRI Healthcare also announced today that its board of trustees has declared a quarterly cash distribution in the amount of $0.10 per Unit for the third quarter of 2025, payable on October 20, 2025, to unitholders of record as of September 30, 2025. Normal Course Issuer Bid During the three months ended June 30, 2025, DRI Healthcare repurchased and cancelled 958,279 Units under its NCIB for an aggregate amount of $9.1 million at a weighted average price of $9.54 per Unit. As previously announced, DRI Healthcare received approval on May 9, 2025 from the TSX to acquire, from time to time, if considered advisable, up to an aggregate of 3,148,536 Units for cancellation. Purchases will conclude on the earlier of the date on which DRI Healthcare has purchased the maximum number of Units permitted under the NCIB and May 19, 2026. In connection with the NCIB, DRI Healthcare established an AUPP where by Units of DRI Healthcare may be repurchased at the discretion of a dealer to the AUPP using commercially reasonable efforts and subject to trading parameters defined in the AUPP. Subsequent to June 30, 2024, DRI Healthcare repurchased an additional 208,580 Units at an average price of US$10.24, totaling $2.1 million under the AUPP. Second Quarter 2025 Conference Call & Webcast As previously announced, management will hold a conference call on Thursday, August 14, 2025 at 8:00 a.m. (ET) to review DRI Healthcare's 2025 second quarter results. You can join the call by dialing 1-888-699-1199 or 416-945-7677 approximately 15 minutes prior to the call to secure a line. A live webcast of the conference call, including a slide presentation, will be available at Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived on DRI Healthcare's website following the call date. Non-GAAP Financial Measures The reconciliations of non-GAAP financial measures and non-GAAP ratios for the three and six months ended June 30, 2025 and 2024 to the most directly comparable measures calculated in accordance with IFRS are presented below. Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts Total Cash Receipts refers to Total Cash Royalty Receipts plus cash receipts from all products. Total Cash Receipts includes cash receipts from interest as well as non-recurring cash receipts. Total Cash Royalty Receipts refers to aggregate cash royalty receipts and milestone royalty receipts from DRI Healthcare's portfolio of royalty assets and forms part of Total Cash Receipts. Because of the lag between when DRI Healthcare records royalty income and receives the corresponding cash payments on its royalties and milestones, management believes Total Cash Receipts and Total Cash Royalty Receipts are useful measures when evaluating DRI Healthcare's operations, as they represent actual cash generated in respect of all royalty assets held during a period. DRI Healthcare also presents Normalized Total Cash Receipts, which refers to Total Cash Receipts adjusted to remove cash receipts that are not expected to recur in the normal course of operations. Management believes that Normalized Total Cash Receipts will assist readers in evaluating the period-over-period performance of DRI Healthcare's royalty portfolio since Normalized Total Cash Receipts only includes cash receipts generated by royalties and other amounts payable pursuant to the terms of DRI Healthcare's royalty assets. There were no adjustments required to normalize cash receipts for the six months ended June 30, 2025 and 2024. Adjusted EBITDA and Adjusted EBITDA Margin Management believes Adjusted EBITDA provides meaningful information about DRI Healthcare's operating cash flows as it eliminates the effects of other non-cash expenses and accruals and income and expenses that are not expected to recur, that have been recorded on the statement of net earnings (loss) and comprehensive earnings (loss). DRI Healthcare refers to EBITDA when reconciling its net earnings (loss) and comprehensive earnings (loss) to Adjusted EBITDA, but does not use EBITDA as a measure of its performance. Management believes that Adjusted EBITDA Margin is a useful supplemental measure to demonstrate the operating efficiency of DRI Healthcare's business on a cash basis. Three months ended Six months ended (thousands of US dollars) June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Comprehensive earnings (loss) (700) (1,905) (2,532) (7,248) [+] Amortization of intangible royalty assets 24,751 25,679 49,496 50,725 [+] Impairment of intangible royalty assets — 820 — 5,200 [-] Other interest income (356) (577) (654) 17,039 [+] Interest expense 9,028 8,641 18,635 — EBITDA 32,723 32,658 64,945 64,417 [+] Royalties receivable, beginning of period 45,006 45,470 62,362 64,082 [-] Royalties receivable, end of period (49,647) (43,542) (49,647) (43,542) [-] Performance fees payable, beginning of period (2,198) (4,916) (1,665) (5,918) [+] Performance fees payable, end of period — — — — [+] Financial royalty assets, beginning of period 55,088 — 57,527 — [-] Financial royalty assets, end of period (54,184) — (54,184) — [+] Unrealized loss (gain) on marketable securities 115 — (1,420) — [+] Acquired royalties receivable — — — 3,560 [+] Unit-based compensation 970 4,675 1,430 7,242 [+] Board of trustees' unit-based compensation 2 452 198 556 552 [+] Loss (Gain) on preferred securities 971 (2,176) 971 (2,176) [-] Other loss — 764 — 1,575 [-] Net unrealized loss (gain) on derivative instruments 1,076 (228) 1,156 (1,425) Adjusted EBITDA 30,372 32,903 82,031 88,367 [÷] Normalized Total Cash Receipts 40,152 42,955 102,142 106,472 Adjusted EBITDA Margin 76 % 77 % 80 % 83 % _______________________________ 2 Certain members of the board of trustees elected to be compensated fully or partially in Deferred Units ("DUs") under DRI Healthcare's Omnibus Equity Incentive Plan. Adjusted Cash Earnings per Unit Management believes that Adjusted Cash Earnings per Unit provides meaningful information about DRI Healthcare's performance as it provides a measure of the cash generated by DRI Healthcare's assets on a per Unit basis, excluding cash earnings that are not expected to recur. Corporate Update Further to DRI Healthcare's press release of July 1, 2025, subsequent to end of quarter, DRI Healthcare completed its previously announced transaction to internalize its investment management function. As a result of the transaction, the management agreement with DRI Capital was terminated in exchange for a $48 million termination payment and DRI Healthcare internalized the manager function by acquiring the relevant assets of DRI Capital for a purchase price of $1 million. As a result of the transactions contemplated by the asset purchase agreement, the employees of DRI Capital also transitioned to a subsidiary of DRI Healthcare. DRI Healthcare shares that Mr. Amit Kapur, Chief Financial Officer, will be departing DRI Healthcare at the end of September. "Last summer, Amit graciously stepped in at a pivotal moment, helping to steady DRI Healthcare and lay a stronger foundation. He was instrumental in DRI Healthcare's strategic review, playing a significant leadership role in the evaluation of all options and ultimately facilitating the successful internalization of the manager. On behalf of the board of trustees, the team, and our unitholders, we thank Amit for his exceptional skill and leadership during a demanding period and wish him continued success as he brings that same expertise to his next venture." said Gary Collins, Executive Chair of DRI Healthcare. _____________________ 1 Certain members of the board of trustees elected to be compensated fully or partially in DUs under DRI Healthcare's Omnibus Equity Incentive Plan. About DRI Healthcare DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3.0 billion, acquiring more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol " and in U.S. dollars under the symbol "DHT.U". To learn more, visit or follow us on LinkedIn. Caution concerning forward-looking statements This news release may contain forward-looking information within the meaning of applicable securities legislation. Forward-looking information can generally be identified by the use of words such as "expect", "continue", "anticipate", "intend", "aim", "plan", "believe", "budget", "estimate", "forecast", "foresee", "close to", "target" or negative versions thereof and similar expressions. Some of the specific forward-looking information in this news release may include, among other things, statements regarding DRI Healthcare's ability to execute on its strategy, the potential and timing of royalty payments, the anticipated royalty income and anticipated sales of the products underlying such royalties, and DRI Healthcare's normal course issuer bid. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond DRI Healthcare's control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, the risk that the internalization of DRI Healthcare's manager will not generate the levels of anticipated benefits for DRI Healthcare and its unitholders and those additional risks and uncertainties that are disclosed in DRI Healthcare's most recent annual information form and under "Risk Factors" in DRI Healthcare's Management's Discussion and Analysis. The anticipated royalty terms for products in our portfolio may be shorter than the period of patent protection for the applicable product, depending on many factors, including the entry of generic drugs into the marketplace and competition, all of which are outside our control. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements in this press release. You should not put undue reliance on forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, the actual results, performance or achievements of DRI Healthcare could differ materially from the results expressed in, or implied by, any forward-looking statements. Certain assumptions underlying the forward-looking information in this news release include: DRI Healthcare's assumptions regarding demand and growth in pharmaceutical sales, R&D and opportunities for royalty investing; the competitive environment in which DRI Healthcare operates; DRI Healthcare's ability to implement its growth strategies; DRI Healthcare's ability to obtain financing and maintain its existing financing on acceptable terms; DRI Healthcare's ability to maintain good business relationships with marketers and other industry partners; timely receipt of cash royalty receipts; expectations regarding the duration of royalties; DRI Healthcare's ability to keep pace with changing consumer preferences; the absence of material adverse changes in DRI Healthcare's industry or the global economy; currency exchange and interest rates; the impact of competition; the changes and trends in DRI Healthcare's industry or the global economy; and stability in laws, rules, regulations and global standards in the pharmaceutical industry. All forward-looking information in this news release speaks as of the date of this news release. DRI Healthcare does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise except as required by law. Additional information about these assumptions and risks and uncertainties is contained in DRI Healthcare's filings with securities regulators, including its latest annual information form and Management's Discussion and Analysis. These filings are also available at DRI Healthcare's website at
Globe and Mail
22 minutes ago
- Globe and Mail
Kontrol Technologies Announces Second Quarter 2025 Financial Results
Kontrol Technologies Corp. ( (OTCQB:KNRLF) (FSE:1K8) ("Kontrol Technologies" or "Kontrol" or "Company") announces its results for the three months and year to date ended June 30, 2025. A complete set of the Financial Statements and Management's Discussion & Analysis have been filed on SEDAR ( Highlights Net Income positive in Q2 Increase in aggregate cash and marketable securities Continued progression of Kontrol BuildX AI platform 'The Company's cash and marketable securities position gives us the necessary resources to accelerate organic growth plans and to complete potential acquisitions,' says Paul Ghezzi, CEO of Kontrol. 'While the Company has not closed any new acquisitions in recent quarters, we have identified targets and continue the process of performing detailed due diligence reviews. We experienced some softness in the market with customers slowing their spending on capex projects, primarily related to tariff risks, however, maintenance and service solution margins have remained strong. We anticipate a recovery of spending on capex projects in the third and fourth quarters. We continue to service approximately 400 commercial buildings.' Q2 2025 and Year to Date Highlights In Q2 2024, the Company completed the sale of the operational net assets of CEM Specialties Inc. and as such revenue and earnings are lower in 2025 compared to the same period in the prior year. As at June 30, 2025 the Company's aggregate cash and marketable securities balance was $11.6 million, an increase of $400,000 from the previous quarter. Revenues for the three months ended June 30, 2025 were $1.3 million, compared to $3.7 million for the same quarter in the prior year; Revenues for the six months ended June 30, 2025 were $2.8 million, compared to $7.4 million for the same period in the prior year. Gross margin for the six months ended June 30, 2025 was 56%, compared to 58% for the same period in the prior year. Net income for the three months ended June 30, 2025 was $230,592 compared to $12.3 million for the same quarter in the prior year; Net income (loss) for the six months ended June 30, 2025 was $(915,240) compared to $12.9 million for the same period in the prior year. Net income (loss) in 2025 includes income from revaluation of marketable securities. Net income in 2024 includes gain on sale of the CEMSI net assets. Adjusted EBITDA for the six months ended June 30, 2025 was negative $(597,553) compared to $440,037 for the same period in the prior year. The Company had no outstanding interest-bearing bank debt at June 30, 2025. Kontrol BuildX AI – New AI Solution As previously announced, the Company has initiated the development of a new AI driven solution for its customers. 'We see a significant addressable market opportunity to integrate, analyze, and operationalize large volumes of data for our customers using AI. We seek to help our customers enhance operational efficiency, support predictive analytics, and drive outcomes to operate a better building,' continues Ghezzi. Corporate Branding The Company is updating its website and social media platforms. The updated branding is anticipated to be completed by the end of August 2025. Normal Course Issuer Bid During the six months ended June 30, 2025, the Company repurchased 1,362,000 common shares for a total of $235,000. Pursuant to the Normal Course Issuer Bid approved by Cboe Canada, Kontrol may purchase, from time to time, over a period of 12 months starting April 14th, 2025, and ending April 13th, 2026, up to 2,757,858 common shares. The Company has 54,529,169 shares outstanding as at June 30, 2025. Q2 2025 and Year to Date Financial Summary Financial Results Three months ended Six months ended (Unaudited) June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Revenue $1,257,424 $3,654,825 $2,750,807 $7,441,059 Gross profit $739,623 $2,020,525 $1,547,428 $4,352,600 Net income (loss) $230,592 $12,321,014 $(915,240) $12,854,502 Basic and diluted EPS $0.00 $0.21 $(0.02) $0.22 Add/Deduct for Adjusted EBITDA reconciliation: Amortization and depreciation $156,781 $228,334 $312,833 $450,717 Finance expense (income) $(32,155) $91,967 $(62,363) $250,629 Gain on sale of assets - $(13,241,405) - $(13,241,405) Revaluation of marketable securities $(772,724) - $(29,729) - Share based compensation $48,473 $73,637 $96,946 $125,594 Adjusted EBITDA $(369,033) $(526,453) $(597,553) $440,037 Adjusted EBITDA is a non-International Financial Reporting Standards ("IFRS") measure used by management that is not defined by IFRS. Adjusted EBITDA does not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA provides meaningful and useful financial information as these measures demonstrate the operating performance of the business excluding non-cash charges. "Adjusted EBITDA" is calculated as net income or loss before interest, income taxes, amortization, and depreciation, share based compensation, acquisition related expenses, listing expense, gain or loss on sale of assets, revaluation and impairment of assets. Readers are cautioned that Adjusted EBITDA should not be construed as an alternative to net income as determined under IFRS; nor as an indicator of financial performance as determined by IFRS; nor a calculation of cash flow from operating activities as determined under IFRS; nor as a measure of liquidity and cash flow under IFRS. The Company's method of calculating Adjusted EBITDA may differ from methods used by other companies and, accordingly, the Company's Adjusted EBITDA may not be comparable to similar measures used by any other company. Kontrol Technologies Corp. Kontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol provides solutions and services to its customers to improve energy management and accelerate the sustainability of all buildings. Additional information about Kontrol Technologies Corp. can be found on its website at and by reviewing its profile on SEDAR at Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may", "will", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy. Where Kontrol expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated. However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all; that those technologies will not prove as effective as expected; those customers and potential customers will not be as accepting of the Company's product and service offering as expected; and government and regulatory factors impacting the energy conservation industry. Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
